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The Receiver Operating Characteristic (ROC) curve is a widely used tool to evaluate diagnostic and 1 
prognostic biomarker performance1,2,3.  The ROC curve compares the sensitivity and specificity of a 2 
candidate biomarker for a range of potential cut-off values for a biomarker assay – see Figure 1A.  3 
One of the perceived advantages of the ROC curve is that it is independent of the prevalence of the 4 
disease and captures the two key misclassification errors – false positive errors and false negative 5 
errors – as a function of biomarker cut-offs.   6 
However, when teaching, it is important to emphasize that while the ROC curve is independent of 7 
the prevalence rate, the translational performance of a biomarker test in the clinic is critically 8 
dependent upon that very same prevalence rate4,5.  While this is well understood by statisticians, it is 9 
not always obvious to scientists and clinicians developing new assays. 10 
For example, the “10-90-50 Rule” states that: 11 
• for a disease with a prevalence of 10%, and 12 
• an assay with both sensitivity and specificity greater than 90%,  13 
• 50% of patients testing positive are false alarms. 14 
And if the prevalence of the disease is less than 10% then most of our positive diagnostic tests will be 15 
false alarms – see Figure 1B.   16 
In this short note, we present a simple tool permitting practitioners to capture assay performance as 17 
a function of prevalence rates.  Understanding how an assay performs across a range of values for 18 
the prevalence is often critical – both commercially and clinically.  There is often uncertainty 19 
surrounding the estimate of prevalence in the first place.  Then, once the test is moved into the 20 
clinic, this is compounded by the fact that the prevalence rates vary depending upon how the 21 
patients are selected for testing.  And, even following adoption of the test, the test may be used for 22 
groups of patients for whom the prevalence is rather less than that in the original test population, 23 
making the test virtually worthless. Translational performance is a function of both the ‘true’ disease 24 
prevalence and the clinical selection process for testing4,5.    25 
Rather than ignore prevalence, simple plots of candidate assay performance as a function of 26 
prevalence rate give a more realistic understanding of the likely real-world performance in the clinic, 27 
and a greater understanding of the likely impact of variation in that prevalence on translational 28 
performance in the clinic – see Figure 1B.  Plotting the misclassification rates – False Alarms and 29 
Missed Diagnoses – as a function of possible prevalence rates allows us to focus on misclassification 30 
costs.   31 
In Figure 2, we give a worked example showing prevalence plots for the promising mast cell 32 
activation test for IgE-mediated food allergy6. The sensitivity and specificity of this test are an 33 
impressive 97% and 92% respectively, with a ROC AUC of 0.99 (95% CI: 0.96, 1.00).  While the 34 
number of patients with food allergies who are missed by the assay is reassuringly low, the number 35 
of patients without the disease testing positive is likely to be high, given an estimated prevalence in 36 
the UK of just 6%.  This may, or may not, be acceptable.  In real life, the relative costs associated 37 
with false alarms and missed diagnoses are likely to be very different and must be assessed prior to 38 
the test entering the clinic: a false alarm may simply mean a patient is subjected to further testing; a 39 
missed diagnosis may mean the patient dies.   40 
Prevalence plots focus reviewers on misclassification rates, misclassification costs, and how the 41 
assay will translate to the clinic. Without thoughtful consideration of prevalence rates and the 42 
relative costs of misclassification errors, it is easy to 1) overstate the potential value of a candidate 43 
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biomarker, 2) generate unrealistic expectations of that candidate, 3) incur unnecessary trial costs in 44 
evaluating that candidate, 4) incur opportunity costs in denying patients access to better diagnostic 45 
tests.    46 
We provide an Excel workbook as a teaching tool.  This permits readers to estimate Missed Cases 47 
and False Alarms for an assay with any given sensitivity, specificity for a range of prevalence values. 48 
 49 
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Figure 1:  The 10-90-50 Rule.  While the ROC AUC for our candidate biomarker looks promising 
(A) with a sensitivity and specificity of 90%, the performance of the assay in the clinic depends 
critically on the prevalence of the disease (B).  The false positive and false negative rates are 
both 10%, but if the prevalence of the disease in the test population is 10% then 50% of all 
positive tests will be false alarms. The false alarm rate depends critically upon the prevalence 
in the test population. Plotting test performance as a function of prevalence gives a more 
realistic understanding of likely performance in the clinic.  See text for details.  
 
Figure 2:  Prevalence plots for the mast cell activation assay.  While the assay looks promising - with a 
sensitivity of 97%, specificity of 92% and a ROC AUC of 0.99 - translation to the clinic depends critically 
upon the prevalence in the test population. As the prevalence increases, the percentage of missed cases 
increases and the percentage of false alarms decreases.  If the prevalence rate is zero then any positive test 
results are false positives and the false alarm rate is 100%. If the prevalence rate is 100% then any negative 
tests are false negatives and the missed case rate is 100%.  The vertical line shows the estimated prevalence 
of IgE-mediated food allergy at 6%.  At this prevalence rate, approximately 56% of all positive tests will be 
false alarms – see Supplementary Excel Workbook Bench-2-Bedside.xls. 
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